<?xml version="1.0" encoding="UTF-8"?>
<p>For anti-IAV drugs, currently, NA inhibitors (Relenza
 <sup>TM</sup> and Tamiflu
 <sup>TM</sup>) are applied clinically as anti-influenza drugs [
 <xref rid="B218-viruses-12-00376" ref-type="bibr">218</xref>]. These drugs inhibit the activity of NA by preventing viral budding [
 <xref rid="B21-viruses-12-00376" ref-type="bibr">21</xref>]. In addition, cap-dependent endonuclease inhibitor (Baloxavir Marboxil) targeting PA is also applied against influenza A and B virus infection [
 <xref rid="B219-viruses-12-00376" ref-type="bibr">219</xref>]. Our progressing understanding of the IAV life cycle of the virus and IAVâ€“host interaction could contribute to anti-influenza drug design.
</p>
